Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.

Mosquito
  • R21/Matrix-M becomes the second malaria vaccine candidate ever to start a phase III licensure trial
  • This builds on the recent finding of high level efficacy of this vaccine in a phase IIb trial in children in Burkina Faso, published today in The Lancet
  • The first phase III trial doses were administered by the team at the Malaria Research and Training Centre, Bamako, Mali, one of five trial sites across West and East Africa
  • The malaria vaccine was designed at the Jenner Institute, University of Oxford, who have partnered with the Serum Institute of India for commercial development

The trial will assess efficacy and safety in 4800 children across five sites in Burkina Faso, Kenya, Mali and Tanzania. A double-blind, randomised, controlled trial, where participants, aged 5-36 months, receive three vaccinations 4 weeks apart and a booster vaccination 1 year later, it will allow the vaccine to be assessed in areas of differing malaria transmission and seasonality.

Read the full story on the University of Oxford website

Similar stories

Student Prizes for Biomedical Sciences and Medicine 2021-2022

Congratulations to all our Biomedical Sciences students and Medicine students who have been awarded prizes during the 2021-2022 academic year.

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Researchers discover novel form of adaptation in the auditory system

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have found that the auditory system adapts to the changing acoustics of reverberant environments by temporally shifting the inhibitory tuning of cortical neurons to remove reverberation.

20 minutes of daily exercise can keep teens' doctors away

Teenagers should exercise vigorously for at least 20 minutes per day to reap increased cardiorespiratory fitness (CRF), according to a cross-sectional study from the UK led by University of Oxford researchers.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.